CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About CADTH What We Do Programs and Services CADTH Reimbursement Review Canakinumab

Canakinumab

Last Updated: November 24, 2015

Result type: Reports

Project Number: SR0463-000

Product Line: Reimbursement Review

Generic Name: Canakinumab

Brand Name: Ilaris

Manufacturer: Novartis Pharmaceuticals Inc.

Therapeutic Area: Systemic Juvenile Idiopathic Arthritis

Indications: Systemic juvenile idiopathic arthritis

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: June 17, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions

Canakinumab

Files